Abstract P1-17-01: Response of persistent metastatic ER+/Her2- breast cancer treated with fulvestrant plus enzalutamide
Jennifer K. Richer(University of Colorado Anschutz Medical Campus), Anthony Elias(University of Colorado Cancer Center), Elena Shagisultanova(University of Colorado Anschutz Medical Campus), Tessa McSpadded(University of Colorado Anschutz Medical Campus), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Peter Kabos(University of Colorado Anschutz Medical Campus), Dexiang Gao(University of Colorado Cancer Center), Jennifer R. Diamond(University of Colorado Anschutz Medical Campus), Rosa I. Gallagher(George Mason University), Sharon B. Sams(University of Colorado Denver), Nicole S. Spoelstra(University of Colorado Anschutz Medical Campus), Gloria Crawford(Cancer Clinic), Gregory A. Vidal(West Cancer Center), Julia Wulfkuhlue(George Mason University), Anosheh Afghahi(University of Colorado Anschutz Medical Campus), Virginia F. Borges(University of Colorado Anschutz Medical Campus), Alyse Winchester(University of Colorado Anschutz Medical Campus), José Mayordomo(Royal Bournemouth Hospital)
Cited by 1
Related Papers
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2018|1.6k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
|Nature Medicine|1995|1.1k
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
|New England Journal of Medicine|2019|846